- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | YD Bio Limited Showcases Its Innovative Diagnostic and Precision Medicine Portfolios at the 9th Healthcare EXPO TAIWAN | 1 | GlobeNewswire (USA) | ||
| 02.12. | YD Bio expands cancer detection platform to pancreatic and colorectal cancers | 2 | Investing.com | ||
| 02.12. | YD Bio Limited Expands OkaiDx Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early Detection | 2 | GlobeNewswire (USA) | ||
| YD BIO Aktie jetzt für 0€ handeln | |||||
| 24.11. | FDA-Zulassung für Augenpflegeprodukte beflügelt YD Bio-Aktie | 1 | Investing.com Deutsch | ||
| 24.11. | YD Bio receives FDA clearance for contact lenses and artificial tears | 2 | Investing.com | ||
| 24.11. | YD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome Therapeutics | 226 | GlobeNewswire (Europe) | Taipei, Taiwan, Nov. 24, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and... ► Artikel lesen | |
| 17.11. | YD Bio Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 05.11. | YD Bio Limited: YD Bio and EG BioMed Expand U.S. Access to OkaiDx, a cfDNA-Methylation Blood Test for Post-Treatment Breast Cancer Monitoring | 143 | GlobeNewswire (Europe) | Taipei, Taiwan, Nov. 05, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (NasdaqGM: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and... ► Artikel lesen | |
| 24.10. | YD Bio Ltd - F-1/A, Registration statement for certain foreign private issuers | 1 | SEC Filings | ||
| 20.10. | YD Bio Limited: YD Bio Ltd. Rings Nasdaq Opening Bell to Celebrate Listing under Ticker YDES | 4 | GlobeNewswire (USA) | ||
| 10.10. | YD Bio Limited: YD Bio Business Partner EG Biomed Achieves CAP Accreditation, Advancing U.S. Clinical Testing Capabilities | 192 | GlobeNewswire (Europe) | Taipei, Taiwan, Oct. 10, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and... ► Artikel lesen | |
| 01.10. | YD Bio Limited reports 1H results | 2 | Seeking Alpha | ||
| 30.09. | YD Bio Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 26.09. | YD Bio meldet COO-Rücktritt und plant Registrierung öffentlicher Optionsscheine | 1 | Investing.com Deutsch | ||
| 23.09. | YD Bio Ltd - F-1, Registration statement for certain foreign private issuers | 1 | SEC Filings | ||
| 19.09. | YD Bio Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 08.09. | YD Biopharma Ltd - 15-15D, Suspension of duty to report | 2 | SEC Filings | ||
| 28.08. | YD Bio Limited Announces Closing of Business Combination and Listing on the Nasdaq Global Market | 285 | GlobeNewswire (Europe) | Strategic Move Positions YD Bio Limited for Accelerated Innovation and Market ExpansionTrading of common stock and warrants of the new public company, YD Bio Limited, is expected to commence on the... ► Artikel lesen | |
| 20.08. | YD Bio Ltd - 8-A12B, Registration of securities | 2 | SEC Filings | ||
| 15.08. | Breeze Holdings Acquisition Corp. Shareholders Approve Business Combination with YD Biopharma Limited | 230 | GlobeNewswire (Europe) | Transaction Expected to Close in the Coming Days Combined Company to be Named YD Bio Limited and Expectedto Trade on Nasdaq Under Ticker Symbol "YDES" IRVING, Texas, Aug. 15, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| STRUCTURE THERAPEUTICS | 67,06 | -0,56 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs | SAN FRANCISCO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| COGENT BIOSCIENCES | 42,110 | +5,17 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 77,08 | +0,72 % | Apogee Therapeutics stock initiated with Buy rating at Deutsche Bank | ||
| HARMONY BIOSCIENCES | 40,510 | +2,32 % | Harmony Biosciences Holdings, Inc.: Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress | Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that it will present data from its rare epilepsy pipeline at the 36th International Epilepsy Congress (IEC) being held August 30... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 71,83 | +0,32 % | Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity | ||
| LENZ THERAPEUTICS | 18,140 | -25,96 % | LENZ Therapeutics, Inc. - 8-K, Current Report | ||
| QIAGEN | 38,345 | -0,67 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 29,020 | -1,53 % | Amit Munshi joins Arcutis board as founder Chaudhuri retires | ||
| ARCELLX | 71,86 | -1,14 % | Stifel upgrades Arcellx stock, cites buying opportunity after share weakness | ||
| MINERALYS THERAPEUTICS | 36,890 | +2,33 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup | - Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 33,040 | +4,62 % | Olema Pharmaceuticals stock price target raised to $45 at H.C. Wainwright | ||
| KYMERA THERAPEUTICS | 89,67 | +2,12 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | WATERTOWN, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 41,590 | +1,41 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution | - ARCALYST® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth -- ARCALYST 2025 expected net product revenue raised to $670 - $675 million -- KPL-387... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,330 | -5,46 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| IMMUNOVANT | 26,430 | +6,53 % | Immunovant: 550-Millionen-Dollar-Kapitalerhöhung und neue Studiendetails |
YD BIO LIMITED gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -0,72 % bei einem Aktienkurs von 12,480 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu YD BIO LIMITED finden Sie auf Wallstreet Online.